The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) is being challenged by the introduction of the highly effective IL-17 inhibitors. In particular, the uptake of secukinumab (Novartis’s Cosentyx) has been remarkable in the first two years of its launch, but the agent faces competition from the newer IL-17 inhibitors—ixekizumab (Eli Lilly’s Taltz) and brodalumab (Valeant/LEO Pharma/Kyowa Hakko Kirin’s Siliq/Kyntheum/Lumicef). With the approval and launch of Janssen’s IL-23 inhibitor, guselkumab (Tremfya), another effective drug class has been introduced into this increasingly competitive market. Additionally, the landscape for the established biologics will change further with the increasing availability and use of biosimilars.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 20 country-specific interviews with thought leaders.
Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of psoriasis; number of diagnosed prevalent cases of psoriasis by severity.
Emerging therapies: Phase II: 14drugs; Phase III/preregistration: 7 drugs; coverage of select preclinical and Phase I products.